In summary, we have shown that mutated KRAS is an independent negative prognostic factor for survival in NSCLC stage III disease treated with combined chemoradiotherapy or bioradiotherapy, and the prevalence of KRAS mutations and EGFR mutations are as expected in this northern European population. This evidence concerns the gene KRAS and non-small cell lung carcinoma.